PAPaula Aristizabal

Paula Aristizabal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paula Aristizabal has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of S-IMCICA_V.2: A User-Centered Educational and Decision-Support mHealth App for Early Detection of Childhood Cancer

    by Elvia Karina Grillo, Oscar Ramirez, Catalina Niederbacher, Jesús Ardila, Santiago Bolivar, Patricia Montenegro, Michael Lauzardo, Paula Aristizabal

  • Enhancing Clinical Skills Among Non‐Intensivists Caring for Critically Ill Children With Cancer: A Transnational Educational Workshop

    by Valerie Vernot, Angelica Martinez, Santiago Bolivar, Victoria García, Magdalena Pérez, Gabriela Aguiar, Maribel Ramírez, Rebeca Rivera‐Gomez, Jeremy Landeo, William Roberts, et al.

    Over 90% of children with cancer live in low‐ and middle‐income countries (LMICs), where critically ill children are often managed by non‐intensivists. We implemented a translational, hybrid workshop between Hospital General–Tijuana, Mexico, and Rady Children's Health–San Diego, USA, to enhance non‐intensivists’ knowledge and clinical skills in onco‐critical care. Pre‐ and post‐workshop assessments evaluated knowledge, self‐reported confidence, and satisfaction in 17/20 participants. Knowledge increased by 13.0% (68.8% vs. 81.8%; p < 0.05). Confidence increased (5.9%–41.2% vs. 64.7%–94.1%; p < 0.05) in 6/8 topics: intracranial hypertension, superior vena cava syndrome, febrile neutropenia, septic/adrenal shock, and medullary compression. Satisfaction was high (88.2%). Our low‐cost, context‐adapted, and replicable workshop enhanced onco‐critical care knowledge and confidence among non‐intensivists caring for critically ill children with cancer, enabling transnational collaboration across the United States‐Mexico border.

  • Co‐Development and Usability Testing of S‐IMCICA: A User‐Centered Web‐Based E‐Learning Curriculum in Early Childhood Cancer Detection for Primary Care Providers in Colombia

    by Oscar Ramirez, Elvia Karina Grillo, Santiago Bolivar, Patricia Montenegro, Jesús Ardila, Vivian Piedrahita, Paula Aristizabal

    Early detection is critical to improving childhood cancer survival. In 2013, the Pan American Health Organization published the Integrated Management of Childhood Illnesses‐Cancer manual. We found that only 13% ( n = 21/161) of primary care providers (PCPs) in southwestern Colombia were familiar with this manual. In response, we iteratively co‐developed an e‐learning curriculum (S‐IMCICA) with PCPs, oncologists, and health educators, and applied usability testing for refinement (five iterations; usability testing in 919 PCPs). Usability testing showed mean increases in knowledge of 21%–24% (60%–65% vs. 81%–89%; p < 0.01) and excellent usability ratings. Our user‐centered e‐learning curriculum contributes to building capacity among PCPs for early childhood cancer detection in low‐ and middle‐income countries.


  • Cancer Knowledge in Caregivers of Children With Cancer: Associations With Social Determinants of Health

    by Nikhil V. Kumar, Shilpa Nataraj, Kayleigh Kornher, Marcos Real, Brittney Love, Joseph Morales, Bianca P. Perdomo, Courtney D. Thornburg, Paula Aristizabal

    Background: While caregivers of children with cancer must understand their child's cancer diagnosis to navigate complex cancer care, research on caregiver cancer knowledge is scarce. Methods: This cross‐sectional study included caregivers of children with newly diagnosed cancer at Rady Children's Hospital‐San Diego, a large quaternary academic center, between October 2014 and May 2020. Linear and logistic regression models were used to assess whether caregiver cancer knowledge overall and by domain (cancer stage/risk, key differences between clinical trial vs. standard of care) was associated with Social Determinants of Health (SDOH), including health literacy (HL), and socio‐contextual factors. Results: Of 182 caregivers who completed this study, 122 (67.0%) were female, and 86 (47.3%) were Hispanic, of whom 14 (16.3%) used Spanish for medical communication. The average caregiver baseline cancer knowledge score was 40%; IQR [21–59]. In multivariable analysis, limited HL and household income were associated with lower cancer knowledge (for HL: β = −6.60; 95% CI: −12.52, −0.69; p = 0.029; for household income < $60,000: β = −8.14; 95% CI: −13.58, −2.70; p = 0.004) and decreased odds of knowing key differences between clinical trial vs. standard of care (for HL: odds ratio (OR) = 0.27; 95% CI: 0.13, 0.54; p p = 0.036). Hispanic ethnicity (OR = 0.17; 95% CI: 0.04, 0.55; p = 0.005) and household income <$60,000 (OR = 0.14; 95% CI: 0.03, 0.51; p = 0.005) were associated with decreased odds of knowing the correct cancer stage/risk. Conclusion: Hispanic caregivers and those with limited HL tended to have lower baseline knowledge of their child's new cancer diagnosis. Our findings underscore the need for early, tailored interventions to increase cancer knowledge and facilitate healthcare navigation in underserved populations.


  • Open Access

    VIGICANCER: Understanding Real-World Childhood Cancer Clinical Outcomes in Colombia to Inform Cancer Control Policy

    by Oscar Ramirez, Santiago Bolivar, Monica L. Quijano-Lievano, Vivian Piedrahita, Jesús Ardila, Andres Portilla, Elvia Grillo, Maria Alvarez, Maria X. Castro, Viviana Lotero, et al.

    Monitoring clinical outcomes is essential for cancer control. Yet, population-based surveillance systems are scarce in low- and middle-income countries (LMICs). To fill a real-world population-based data gap on cancer outcomes in Colombia, we implemented VIGICANCER in 2009, a nationwide childhood cancer clinical outcomes surveillance system to collect, analyze, and disseminate valid, reliable, and timely population-based information. This Special Article describes the evolution and impact of VIGICANCER, contextualized within the Latin-American population-based data systems landscape. VIGICANCER registers children (12,000 patients, covering 55%-60% of the projected new childhood cancer cases nationwide yearly. We describe clinical characteristics, 5-year overall survival (OS), and event-free survival (EFS) in a 14-year cohort of Colombian children with cancer. Kaplan-Meier and log-rank tests were used for survival analyses. From 2009 to 2023, VIGICANCER analyzed 9,986 patients and 3,626 events, including 3,081 deaths. The cohort's median age was 8.6 years (IQR, 4.0-13.7), 55.0% of patients (n = 5,489/9,986) were male, 8.0% (n = 757/9,479) were Black, 3.3% (n = 206/6,165) were Indigenous, and 49.9% (n = 4,849/9,711) had public insurance. Five-year OS and EFS were 63.3% (SE, 0.6) and 57.9% (SE, 0.6), respectively. VIGICANCER yields meaningful and actionable population-based data on the local standard of care, guiding data-driven multilevel interventions to improve survival. VIGICANCER provides a reproducible, equity-focused model for LMIC, demonstrating how real-world data inform cancer control policy to reduce survival disparities and advance the goals of the WHO Global Initiative for Childhood Cancer.


  • Open Access

    Building a transdisciplinary network to improve survival in children with cancer in Colombia: seeds to forests

    by Andres Portilla, Eliana Lopez-Baron, Oscar Ramirez, Eileen Fonseca, Santiago Bolivar, Vivian Piedrahita, Monica L. Quijano-Lievano, Karen González, Jesús Ardila, Patricia Montenegro, et al.

    Childhood cancer mortality is disproportionately higher in low- and middle-income countries than high-income countries. The World Health Organization Global Initiative for Childhood Cancer aims for a survival of 60% by 2030. This initiative prioritizes timely diagnosis, access to standardized therapy and supportive care, and prompt management of treatment-related complications. Collaborative work is linked to better performance of health systems and delivery of high-quality care. While collaborative strategies between high- and lower-income countries can advance cancer care in low- and middle-income countries, local and regional initiatives are essential to improve clinical outcomes. The high treatment-related mortality in children with cancer in low- and middle-income countries highlights the critical need to collaborate. To decrease treatment-related mortality in children with cancer in Colombia, a new model of transdisciplinary collaboration was built among Colombian scientific societies (pediatrics, pediatric hematology/oncology, infectious diseases, critical care), academic institutions, grassroots foundations, and the Colombian Childhood Cancer Clinical Outcomes Surveillance System: VIGICANCER. The network supports resource and knowledge exchange to tackle public health challenges related to accessing cancer care for children. It enables the design of targeted and tiered multilevel interventions to enhance quality of care for Colombian children and adolescents with cancer. This transdisciplinary network aims to improve survival in Colombian children with cancer and close the gap with high-income countries by establishing data-informed targets and developing a strategic roadmap to address sepsis, the most actionable cause of treatment-related mortality. Our ultimate goal is to reduce the number of years of life lost, thereby supporting societal progress in Latin America.


  • Open Access

    Pediatric Craniopharyngioma Survival Outcomes at the U.S.-Mexico Border: Results from a Cross-Border Neuro-Oncology Program

    by Alexander Tenorio, Michael G. Brandel, Gautam R. Produturi, Rebeca Rivera-Gomez, Mario Ornelas, Maribel Ramirez, Gabriela Tamayo, Angelica Martinez, David Gonda, William Roberts, et al.


  • Open Access

    Suplemento Especial - Resúmenes de Investigación: XXXVI Congreso de Sociedad Latinoamericana de Oncología Pediátrica (SLAOP) y XXIII Congreso de la Asociación Colombiana de Hematología y Oncología Pediátrica – Cali, junio del 2025

    by Monica Quijano-Lievano, Paula Aristizabal, Eduardo Beltran, Eileen Fonseca, Carlos Castro, Amaranto Suárez, Isabel Sarmiento, Santiago Bolivar, Margarita Quintero, Adriana Linares, et al.


  • Open Access

    Colaboración como estrategia para mejorar la atención del cáncer infantil en países de ingresos bajos y medios: El modelo de VIGICANCER en Colombia

    by Oscar Ramirez, Vivian Piedrahita, Santiago Bolívar, Monica Quijano-Lievano, Viviana Lotero, María Castro, Margarita Quintero, Diego Medina, Roberto Jaramillo, Andrés Portilla, et al.

    Introducción: Colaborar en oncología pediátrica permite abordar y entender a fondo problemáticas complejas en salud como las disparidades en la supervivencia de cáncer infantil en países de ingresos bajos y medios. Describimos la implementación de VIGICANCER, el sistema de vigilancia de desenlaces clínicos en cáncer infantil de Colombia, un ejemplo de colaboración enfocado en mejorar la supervivencia de niños y adolescentes con cáncer en nuestro país. Métodos: diversas iniciativas de colaboración se han establecido en países de ingresos bajos y medios, que demuestran avances en nuestro entendimiento de los mecanismos que contribuyen a inequidades en nuestros países. Se destacan proyectos y programas encauzados a mejorar los desenlaces de los niños con cáncer. Estas iniciativas incluyen programas de “hermanamiento”, alianzas nacionales, regionales, internacionales y conformación de grupos cooperativos de investigación. Resultados: entre estas iniciativas se destaca VIGICANCER, establecido en alianza entre el Registro Poblacional de Cáncer de Cali (RPCC), la Fundación de Pediatras Oncólogos y Hematólogos (POHEMA) y la Asociación Colombiana de Oncología y Hematología Pediátrica (ACHOP). Este se ha posicionado como referente de colaboración e investigación en América Latina, contribuyendo con importantes lecciones para su réplica en otros países de ingresos bajos y medios. Conclusiones: VIGICANCER ha establecido el precedente para futuras rutas de trabajo colaborativas enfocadas en incluir la epidemiología del cáncer y los mecanismos causantes de disparidades en los desenlaces clínicos en cáncer infantil en Colombia, con el objetivo final de mejorar de manera equitativa la supervivencia en niños y adolescentes con cáncer en nuestro país y en América Latina.


  • Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations

    by Josué Hernández-Benítez, Alejandra López-Azcarraga, Jamie E. Flerlage, Sharon Castellino, Paula Aristizabal, Bradford S. Hoppe, Sarah A. Milgrom, Mario José Aguiar de Paula, Raymond B. Mailhot Vega

    PURPOSE: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy is used commonly for pediatric Hodgkin lymphoma (pHL) in low- and middle-income countries. The role of radiotherapy (RT) after ABVD in pHL is uncertain. MATERIALS AND METHODS: We conducted a systematic review to explore the use of ABVD with or without RT in pHL. Key clinical questions included the number of cycles of ABVD, indications for and dose of RT, and outcomes by risk group. A search was performed in PubMed. Articles reporting survival outcomes by risk group were included. RESULTS: Of 97 articles identified in the literature search, nine met inclusion criteria. Chemotherapy consisted of four to six cycles in limited disease and mostly six cycles in advanced disease. Three studies used RT for all patients within a specified risk group. Six studies dictated an adapted RT approach, with 3%-43% of the patients receiving RT for bulky adenopathy, slow early response (SER), and/or incomplete response. Radiation doses ranged between 20 and 36 Gy. The progression-free survival and overall survival at 4-10 years ranged from 84% to 100% and 93%-100% in limited disease and 50%-84.4% and 75%-95.3% in advanced disease, respectively. Studies did not directly assess the impact of certain chemotherapy or RT strategies. Recommendations were made after reviewing outcomes with particular approaches. CONCLUSION: Four cycles of ABVD are recommended for limited disease, and six cycles of ABVD are recommended for advanced disease. In both limited and advanced diseases, RT is recommended with a dose of 20-21 Gy only to sites of bulky and/or SER, with a boost of up to 36 Gy to sites of incomplete response. This approach could spare radiation for at least half of the patients with limited disease and one third of advanced disease.